International Clinical Trial: Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjogren's Syndrome

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07852234) titled 'Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjogren's Syndrome' on Sept. 25.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).

Primary Sponsor: Beijing Tongren Hospital

Condition: Primary Sjogren's Syndrome (pSS)

Intervention: Drug: Blinatumomab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 25, 2026

Target Sample Size: 12

Countries of Recruitment: China

To know more, visit...